1418307-18-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-Benzyl 2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate is used as a potential drug candidate for the treatment of various diseases due to its ability to interact with specific biological targets. Its unique structure and functional groups may allow it to modulate biological pathways and target specific receptors or enzymes, making it a promising candidate for the development of new therapeutic agents.
Used in Drug Discovery and Development:
(S)-Benzyl 2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate is used in drug discovery and development processes to identify and optimize new therapeutic agents. Its chemical properties and potential interactions with biological targets make it a valuable starting point for the design and synthesis of novel compounds with improved pharmacological properties and therapeutic efficacy.
Used in Medicinal Chemistry Research:
(S)-Benzyl 2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate is used in medicinal chemistry research to study its structure-activity relationships and explore its potential as a lead compound for the development of new drugs. Researchers can modify its chemical structure to investigate the effects of different functional groups and substitutions on its biological activity and selectivity, ultimately aiming to optimize its pharmacological properties for specific therapeutic applications.

Upstream product

• 771581-15-8 (3-chloro-pyrazin-2-yl)-methylamine 
• 867165-55-7 2-((3-chloropyrazin-2-yl)methyl)isoindoline-1,3-dione 
• 95-58-9 2-chloro-3-methylpyrazine 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 55557-52-3 2-chloro-3-cyanopyrazine 
• 1418307-17-1 benzyl (S)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)pyrrolidine-1-carboxylate 

Downstream Products

• 1418307-19-3 (S)-benzyl 2-(8-methylimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate 
• 1420478-87-0 benzyl (2S)-2-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate 
• 1420478-88-1 benzyl (2S)-2-(8-amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate 
• 1420478-89-2 (S)-2-((1-(4-(pyridin-2-ylcarbamoyl)phenyl)-8-amino)imidazole[1,5-a]pyrazin-2-yl)pyrrolidine1-yl-carboxylic acid benzyl ester 
• 1420478-90-5 4-{8-amino-3-[(2S)-pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide 
• 1420477-55-9 (S)-4-(3-(1-Acryloylpyrrolidin-2-yl)-8-aminoimidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide 
• 1420477-56-0 (S,E)-4-(8-amino-3-(1-(4-(pyrrolidin-1-yl)but-2-enoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide 

Relevant academic research and scientific papers

Method for preparing Acalabrutinib, in particular to method for preparing Acalabrutinib

The invention relates to the field of chemical synthesis, in particular to a chemical synthesis method for preparing Acalabrutinib. The synthesis method of the compound 3 is optimized, wherein the cyano compound 2 is reduced to obtain the compound 3 by adopting a method of generating borane in situ under the conditions of indium trichloride and sodium borohydride. The method is simple and convenient to operate, a special reaction container and hydrogen are not needed for reduction, a high-risk material catalyst nickel is prevented from being adopted, and large-scale production is facilitated.In the preparation of the compound 15, water is used as a solvent, equivalent hydrogen peroxide is added to react the compound 13 with the compound 14 to prepare the compound 15, so that the method iseconomic and environment-friendly, the post-treatment is simple and convenient, and the reaction liquid is directly subjected to centrifugal operation; in addition, the yield is high and can reach 90% or above; and the compound 15 is high in purity and does not need to be further purified, so that the technology can satisfy the requirements of industrial production.

Preparation method capable of acalabrutinib being used for treating leukemia

The invention relates to a preparation method of acalabrutinib capable of being used for treating leukemia. The synthesis method of the compound 3 is optimized, so that according to the method, the cyano compound 2 is reduced to obtain the compound 3 by adopting a method of generating borane in situ under the conditions of indium trichloride and sodium borohydride. The method is simple and convenient to operate, a special reaction container and hydrogen are not needed for reduction, a high-risk catalyst nickel is prevented from being adopted, and large-scale production is facilitated; in the preparation of the compound 8, under the condition of a catalyst, large-scale preparation is realized by adding an ammonia water closed system, so that a method of introducing ammonia gas at an extremely low temperature is avoided, and large-scale production is facilitated.

PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-A]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE

The present disclosure relates, in general, to improved processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)-benzamide, particularly large-scale processes for manufacturing 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide and intermediates used in such processes.

PROCESSES TO PRODUCE ACALABRUTINIB

The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor.

IMIDAZOPYRAZINE INHIBITORS OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE

In some embodiments, the invention relates to an interleukin-2- inducible T-cell kinase (ITK) inhibitor of formula (I) or a pharmaceutically acceptable salt thereof, or to pharmaceutical compositions comprising these compounds and to their use in the trea

IMIDAZOPYRIDINAMINE PHENYL DERIVATIVE AND USE THEREOF

The present invention relates to imidazopyridinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and

The compounds of structure containing conjugated zincon, its pharmaceutical composition and use thereof (by machine translation)

The present invention relates to compounds having a structure containing conjugated zincon, its pharmaceutical composition and use, and in particular relates to the general formula (I) or a salt thereof to the compound represented by the, pharmaceutical compositions thereof, and its as BTK inhibitors and/or B cell activation inhibitor, for the prevention or treatment B cell activity with abnormal and/or the use of the BTK-related diseases. The compounds of lymphoma, breast cancer, liver cancer, colon cancer, gastric cancer, such as lung cancer and cervical cancer cell has better lethal effect, note has potential for the treatment of cancer and self-immune diseases related to potential. (by machine translation)

Novel imidazo[1,5-a]pyrazine Bruton's kinase inhibitor

The invention relates to a novel imidazo[1,5-a]pyrazine Bruton's kinase inhibitor and an application thereof. The novel imidazo[1,5-a]pyrazine Bruton's kinase inhibitor has a structure represented bya formula (I) shown in the description. The compound with the structure represented by the formula (I) shown in the description has a very good inhibiting effect on activity of a Bruton's kinase, andthe median inhibitory concentration of the compound is generally 10mol/L or less. Simultaneously, the compound with the structure represented by the formula (I) prepared in the embodiments of theinvention shows definite antiphlogistic activity on different animal models.

BTK INHIBITORS TO TREAT SOLID TUMORS THROUGH MODULATION OF THE TUMOR MICROENVIRONMENT

In certain embodiments, the invention includes therapeutic methods of using a BTK inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.

THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR

Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.